Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell‐derived hepatocytes
Liver International · 2023
DOI: 10.1111/liv.15655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2023. Verfasst von Frauke Lange und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture between Medical School Hannove…. Hauptthemen laut MEDLINE: Hepatitis Delta Virus, Hepatitis D. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background
Human pluripotent stem cell (hPSC)‐derived hepatocyte‐like cells (HLCs) are a valuable model to investigate host‐pathogen interactions of hepatitis viruses in a mature and authentic environment. Here, we investigate the susceptibility of HLCs to the hepatitis delta virus (HDV).
Methods
We differentiated hPSC into HLCs, and inoculated them with infectious HDV produced in Huh7 NTCP . HDV infection and cellular response was monitored by RTqPCR and immunostaining.
Results
Cells undergoing hepatic differentiation become susceptible to HDV after acquiring expression of the viral receptor Na + ‐taurocholate co‐transporting polypeptide (NTCP) during hepatic specification. Inoculation of HLCs with HDV leads to detection of intracellular HDV RNA and accumulation of the HDV antigen in the cells. Upon infection, the HLCs mounted an innate immune response based on induction of the interferons IFNB and L, and upregulation of interferon‐stimulated genes. The intensity of this immune response positively correlated with the level of viral replication and was dependant on both the JAK/STAT and NFκB pathway activation. Importantly, this innate immune response did not inhibit HDV replication. However, pre‐treatment of the HLCs with IFNα2b reduced viral infection, suggesting that ISGs may limit early stages of infection. Myrcludex efficiently abrogated infection and blocked innate immune activation. Lonafarnib treatment of HDV mono infected HLCs on the other hand led to exacerbated viral replication and innate immune response.
Conclusion
The HDV in vitro mono‐infection model represents a new tool to study HDV replication, its host‐pathogen interactions and evaluate new antiviral drugs in cells displaying mature hepatic functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture between Medical School Hannover (MHH) and Helmholtz Centre for Infection Research (HZI), Hannover, G…
- Institut für Molekularbiologie, Medizinische Hochschule Hannover, Hannover, Germany.
- Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany.
- ReMediES, Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.
- German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
- Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.
ORCID-Profile: Arnaud Carpentier
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Lange, F., Garn, J., Anagho, H. A., Vondran, F. W. R., von Hahn, T., Pietschmann, T., & Carpentier, A. (2023). Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell‐derived hepatocytes. Liver International. https://doi.org/10.1111/liv.15655
Vancouver
Lange F, Garn J, Anagho HA, Vondran FWR, von Hahn T, Pietschmann T, et al. Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell‐derived hepatocytes. Liver International. 2023. doi:10.1111/liv.15655
BibTeX
@article{Lange2023,
author = {Lange, Frauke and Garn, Jonathan and Anagho, Holda A and Vondran, Florian W R and von Hahn, Thomas and Pietschmann, Thomas and Carpentier, Arnaud},
title = {Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell‐derived hepatocytes},
journal = {Liver International},
year = {2023},
doi = {10.1111/liv.15655}
}
EUVIMED